As anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies interrupt these co-inhibitory signal pathways and restore the function of cytotoxic CD8+ T cells, these antibodies have been used to treat many chemo-resistant cancers. Here, CTLA4 is linked to cancer.